BridgeMD
New treatment option for Glaucoma
Official title Retinal Blood Flow and Autoregulation
ClinicalTrials.gov ID: NCT05344274
What this study is testing
What is Isocapnic Oxygen?
Isocapnic Oxygen is an investigational medicine, being studied as a potential treatment for glaucoma.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to establish autoregulation of retinal blood flow in arterioles and capillaries as a biomarker for early primary open angle glaucoma.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 88. Healthy volunteers may be eligible.
You may be able to join if
- age over 18 years
- open angle in gonioscopy (grade 3 or 4 in Shaffer classification)
- refractive error within the range of +3.00 to -8.00 diopters (4) best-corrected visual acuity 20/25 or better (5) Individuals recruited will be in...
You likely can't join if
- corneal abnormalities or other conditions preventing reliable applanation tonometry
- retinal disease affecting retinal nerve fiber layer thickness such as vitreomacular traction as determined by a glaucoma specialist
- secondary glaucoma
- history of prior ocular surgery other than uncomplicated cataract surgery or laser trabeculoplasty
- inability to safely be off of glaucoma medications for 4 weeks
- inability to obtain OCT angiography data due to excessive eye motion or inability to fixate
See the full eligibility criteria
- age over 18 years
- open angle in gonioscopy (grade 3 or 4 in Shaffer classification)
- refractive error within the range of +3.00 to -8.00 diopters (4) best-corrected visual acuity 20/25 or better (5) Individuals recruited will be in one of the 3 groups: 1) Early Glaucoma as per Hodapp-Anderson-Parrish...
- corneal abnormalities or other conditions preventing reliable applanation tonometry
- retinal disease affecting retinal nerve fiber layer thickness such as vitreomacular traction as determined by a glaucoma specialist
- secondary glaucoma
- history of prior ocular surgery other than uncomplicated cataract surgery or laser trabeculoplasty
- inability to safely be off of glaucoma medications for 4 weeks
- inability to obtain OCT angiography data due to excessive eye motion or inability to fixate
- unreliable visual fields
- any history of smoking in the past 6 months
- cataract greater than lens opacity classification system (LOCS) II Grade≥2
- diagnosis of diabetes, hypertension, or other known vascular disorder such as vasculitis
The study team makes the final eligibility decision.
Where it's taking place
- Baltimore, Maryland, United States
- Silver Spring, Maryland, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 88 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Baltimore, Maryland, United States; Silver Spring, Maryland, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.